Zobrazeno 1 - 10
of 132
pro vyhledávání: '"H. Kirschbaum"'
Autor:
Olatoyosi Odenike, Wendy Stock, Richard A. Larson, Walter M. Stadler, L. Austin Doyle, Scott E. Smith, Sachdev P. Thomas, Philip Dy, Ehab L. Atallah, Loren Joseph, Poluru L. Reddy, Kevin Shannon, Greg Koval, Xavier Poire, Margaret Green, Harry P. Erba, Theodore Karrison, Mark H. Kirschbaum, Leslie Popplewell, Rangesh Kunnavakkam, Ernesto Diaz-Flores, Neil M. Iyengar, Emily Curran, Nitin Jain
PDF file - 339K, Flow cytometry histograms of serial levels of p-ERK and p-mTOR in patient samples.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::942e3eb94da5a8d19a61ca810d5f59a7
https://doi.org/10.1158/1078-0432.22448649.v1
https://doi.org/10.1158/1078-0432.22448649.v1
Autor:
Olatoyosi Odenike, Wendy Stock, Richard A. Larson, Walter M. Stadler, L. Austin Doyle, Scott E. Smith, Sachdev P. Thomas, Philip Dy, Ehab L. Atallah, Loren Joseph, Poluru L. Reddy, Kevin Shannon, Greg Koval, Xavier Poire, Margaret Green, Harry P. Erba, Theodore Karrison, Mark H. Kirschbaum, Leslie Popplewell, Rangesh Kunnavakkam, Ernesto Diaz-Flores, Neil M. Iyengar, Emily Curran, Nitin Jain
Purpose: The clinical relevance of targeting the RAS/RAF/MEK/ERK pathway, activated in 70% to 80% of patients with acute myelogenous leukemia (AML), is unknown.Experimental Design: Selumetinib is an oral small-molecule inhibitor of MAP–ERK kinase (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03c834fe75eeacbfcb60b91c852a1e2e
https://doi.org/10.1158/1078-0432.c.6521448
https://doi.org/10.1158/1078-0432.c.6521448
Autor:
Olatoyosi Odenike, Wendy Stock, Richard A. Larson, Walter M. Stadler, L. Austin Doyle, Scott E. Smith, Sachdev P. Thomas, Philip Dy, Ehab L. Atallah, Loren Joseph, Poluru L. Reddy, Kevin Shannon, Greg Koval, Xavier Poire, Margaret Green, Harry P. Erba, Theodore Karrison, Mark H. Kirschbaum, Leslie Popplewell, Rangesh Kunnavakkam, Ernesto Diaz-Flores, Neil M. Iyengar, Emily Curran, Nitin Jain
PDF file - 50K, Primers for KIT gene mutation testing.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9226ecc2eccc4b8fe30a449ca144fbf5
https://doi.org/10.1158/1078-0432.22448646
https://doi.org/10.1158/1078-0432.22448646
Autor:
Mark H. Kirschbaum, Yun Yen, Stephen J. Forman, Richard Jove, Patrick Ventura, Jun Wu, Claudia M. Kowolik, Pamela M. Dino, Anna Scuto, Leo Kretzner
Supplementary Table 1 from Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::041200c30d29921c8a9b77906d06736f
https://doi.org/10.1158/0008-5472.22395186
https://doi.org/10.1158/0008-5472.22395186
Autor:
Mark H. Kirschbaum, Yun Yen, Stephen J. Forman, Richard Jove, Patrick Ventura, Jun Wu, Claudia M. Kowolik, Pamela M. Dino, Anna Scuto, Leo Kretzner
Supplementary Figure Legends for Table 1 and Figures 1-6 from Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::410042d95d3abb20ffa4e9b64adb3ab6
https://doi.org/10.1158/0008-5472.22395192.v1
https://doi.org/10.1158/0008-5472.22395192.v1
Autor:
Mark H. Kirschbaum, Yun Yen, Stephen J. Forman, Richard Jove, Patrick Ventura, Jun Wu, Claudia M. Kowolik, Pamela M. Dino, Anna Scuto, Leo Kretzner
Supplementary Figures 1-6 from Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bd7a83b7d930075dd8828d2f24fc0e4
https://doi.org/10.1158/0008-5472.22395189
https://doi.org/10.1158/0008-5472.22395189
Autor:
Mark H. Kirschbaum, Yosef Yarden
Publikováno v:
Journal of Cellular Biochemistry. 77:52-60
Cancer chemoprevention trials can be directed at targeting established molecular mechanisms which contribute to neoplasia. One potential target is the ErbB/HER family of growth factor receptors with intrinsic tyrosine kinase activity. This group of f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3c08c8036e659f6043dc18079ea2ac0
https://doi.org/10.1002/(sici)1097-4644(2000)77:34+<52::aid-jcb10>3.0.co
https://doi.org/10.1002/(sici)1097-4644(2000)77:34+<52::aid-jcb10>3.0.co
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Obstetrical & Gynecological Survey. 46:499-508
Although antepartum screening for Group B Streptococcus is not ideal, it may be the most practical approach until rapid tests are proven to be useful in this clinical setting. The efficacy has been established for intrapartum chemoprophylaxis with a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7f7cbcfff9998bf274ec08367687a17
https://doi.org/10.1097/00006254-199108000-00001
https://doi.org/10.1097/00006254-199108000-00001